Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|